Journal article
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
Abstract
BACKGROUND: Since the beginning of the COVID-19 pandemic, no direct antiviral treatment is effective as post-exposure prophylaxis (PEP). Lopinavir/ritonavir (LPV/r) was repurposed as a potential PEP agent against COVID-19.
METHODS: We conducted a pragmatic open-label, parallel, cluster-randomised superiority trial in four sites in Switzerland and Brazil between March 2020 to March 2021. Clusters were randomised to receive LPV/r PEP (400/100 mg) …
Authors
Labhardt ND; Smit M; Petignat I; Perneger T; Marinosci A; Ustero P; Ribeiro MPD; Ragozzino S; Nicoletti GJ; Faré PB
Journal
EClinicalMedicine, Vol. 42, ,
Publisher
Elsevier
Publication Date
December 2021
DOI
10.1016/j.eclinm.2021.101188
ISSN
2589-5370